lifestyle.longislandreport.org

Author: Totus Medicines

Totus Medicines to Present First-in-Class Covalent IRF5 Inhibitor Data at AAI IMMUNOLOGY2026

April 16, 2026
Totus Medicines Presents Phase 1a Clinical Data for TOS-358, a Covalent PI3Ka Inhibitor, at ESMO TAT 2026

March 18, 2026
Totus Medicines to Present Updated Phase 1 Clinical Data for TOS-358 at ESMO Targeted Anticancer Therapies Congress 2026

February 17, 2026